Biologically Active Small Molecules

A phytoestrogen that competitively (vs. 17&beta-estradiol) binds the estrogen receptors ER&alpha (IC50 = 11 nM) and ER&beta (IC50 = 2 nM) and can induce ER-dependent gene expression in isolated cells a weak antagonist of pregnane X receptor

A phytoestrogen that competitively (vs. 17&beta-estradiol) binds the estrogen receptors ER&alpha (IC50 = 11 nM) and ER&beta (IC50 = 2 nM) and can induce ER-dependent gene expression in isolated cells a weak antagonist of pregnane X receptor

The Cayman COX Inhibitor Pack contains a combination of frequently used cyclooxygenase (COX) inhibitors. Each kit contains aspirin, the archetype nonselective, irreversible COX inhibitor.

Essential fatty acid deficiency symptoms include immune system depression and a general state of inflammatory inhibition. CP 24,879 is an inhibitor of arachidonic acid biosynthesis acting via the inhibition of .

Essential fatty acid deficiency symptoms include immune system depression and a general state of inflammatory inhibition. CP 24,879 is an inhibitor of arachidonic acid biosynthesis acting via the inhibition of .

Essential fatty acid deficiency symptoms include immune system depression and a general state of inflammatory inhibition. CP 24,879 is an inhibitor of arachidonic acid biosynthesis acting via the inhibition of .

Essential fatty acid deficiency symptoms include immune system depression and a general state of inflammatory inhibition. CP 24,879 is an inhibitor of arachidonic acid biosynthesis acting via the inhibition of .

An ACC inhibitor (IC₅₀s = 53 and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2, respectively) lowers malonyl-CoA levels and inhibits hepatic fatty acid and triglyceride synthesis both in vitro and in vivo.

An ACC inhibitor (IC₅₀s = 53 and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2, respectively) lowers malonyl-CoA levels and inhibits hepatic fatty acid and triglyceride synthesis both in vitro and in vivo.

An ACC inhibitor (IC₅₀s = 53 and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2, respectively) lowers malonyl-CoA levels and inhibits hepatic fatty acid and triglyceride synthesis both in vitro and in vivo.

An ACC inhibitor (IC₅₀s = 53 and 61 nM for rat liver ACC1 and rat skeletal muscle ACC2, respectively) lowers malonyl-CoA levels and inhibits hepatic fatty acid and triglyceride synthesis both in vitro and in vivo.

A selective inhibitor of PDGFR&beta and PDGFR&alpha kinases (IC₅₀s = 1 and 10 nM, respectively) antiangiogenic and antitumor activity in several in vivo tumor models.